AFT Pharmaceuticals names Stuart Houliston CFO
18/05/2026 09:00 NZST, ADMIN
18 MAY 2026
AFT Pharmaceuticals names Stuart Houliston CFO
AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today advises that Stuart Houliston will commence as the Chief Financial Officer on 15 June 2026.
As advised in March, Malcolm Tubby will retire from the role on 29 May 2026 and Simon Bosley will take over the role in the interim period.
AFT Chair David Flacks said: “We are delighted Stuart has agreed to join the company. Stuart brings financial expertise from both public markets and the accounting profession which will strongly support the future strategy and growth of the business.”
Stuart joins the company from Sanford, New Zealand’s largest integrated fishing and aquaculture company with circa $500 million revenue. Prior to that Stuart was an audit Director at KPMG with a broad range of commercial businesses. He is a chartered accountant and a Master of Science from Oxford University.
AFT Pharmaceuticals Co-Founder and Managing Director Dr Hartley Atkinson said: “AFT is looking forward to working with Stuart to further our growth as we action many initiatives both locally and around the globe.”
Stuart Houliston said: “I am delighted to be joining AFT. The company has a proven record of growth in its 29 years and its ability to develop medicines with a global application. The growth continues to gain momentum, and I am looking forward to being part of the team on this journey.”
Released for, and on behalf of, AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals
AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs . Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.